title: Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease.
abstract: Health-care stakeholders increasingly recognize that the scientific and economic challenges associated with Alzheimer's disease (AD) are simply too great for individual stakeholder groups to address solely from within their own silos. In the necessary spirit of collaboration, we present in this perspective a set of multicountry multistakeholder recommendations to improve the organization of existing AD and dementia care and the development of new treatments. In brief, the five recommendations are (1) health-care systems must make choices regarding the patient populations to be diagnosed and treated, (2) health-care systems should use an evidence-based standard of care, (3) increased collaboration between public and private institutions is needed to enhance research, (4) reimbursement end points need to be agreed on and validated, and (5) innovative business models should be used to spur the introduction of new medicines.
authors.affiliation: Tapestry Networks (US Office), Waltham, MA, USA. Electronic address: pbradley@tapestrynetworks.com.
authors.forename: Patrick
authors.initials: P
authors.lastname: Bradley
authors.affiliation: School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK.
authors.forename: Ron
authors.initials: R
authors.lastname: Akehurst
authors.affiliation: Wolfson Centre for Age Related Diseases, King's College London, London, UK.
authors.forename: Clive
authors.initials: C
authors.lastname: Ballard
authors.affiliation: Brighton & Sussex Medical School, University of Sussex, Brighton, UK.
authors.forename: Sube
authors.initials: S
authors.lastname: Banerjee
authors.affiliation: Clinical Neurochemistry Laboratory, Department of Psychiatry & Neurochemistry, Institute of Neuroscience & Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.
authors.forename: Kaj
authors.initials: K
authors.lastname: Blennow
authors.affiliation: European Health Management Association (EHMA), Brussels, Belgium.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Bremner
authors.affiliation: Federal Institute for Drugs & Medical Devices (BfArM), Bonn, Germany.
authors.forename: Karl
authors.initials: K
authors.lastname: Broich
authors.affiliation: Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Cummings
authors.affiliation: Admiral Nursing, Dementia UK, London, UK.
authors.forename: Karen
authors.initials: K
authors.lastname: Dening
authors.affiliation: Alzheimer Institute (IM2A), Salpêtrière University Hospital, UPMC, Paris, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Dubois
authors.affiliation: Pharmaceuticals Department, Federal Joint Committee (G-BA), Berlin, Germany.
authors.forename: Wiebke
authors.initials: W
authors.lastname: Klipper
authors.affiliation: Biogen Idec, Cambridge, MA, USA (formerly Janssen Alzheimer Immunotherapy Research & Development LLC).
authors.forename: Chris
authors.initials: C
authors.lastname: Leibman
authors.affiliation: Italian Medicines Agency (AIFA), Rome, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Mantua
authors.affiliation: Alzheimer's Disease and Other Cognitive Disorders Unit, Barcelona Clinical Hospital, Barcelona, Spain; Early Detection Programme, Pasqual Maragall Foundation, Barcelona, Spain.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Molinuevo
authors.affiliation: Medicines & Healthcare Products Regulatory Agency (MHRA), London, UK.
authors.forename: Susan
authors.initials: S
authors.lastname: Morgan
authors.affiliation: Italian Medicines Agency (AIFA), Rome, Italy.
authors.forename: Luisa A A
authors.initials: LA
authors.lastname: Muscolo
authors.affiliation: Sanofi S.A., Paris, France (formerly PET Neurology, GE Healthcare).
authors.forename: François
authors.initials: F
authors.lastname: Nicolas
authors.affiliation: Italian Medicines Agency (AIFA), Rome, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Pani
authors.affiliation: Primary Care & Ageing, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
authors.forename: Louise
authors.initials: L
authors.lastname: Robinson
authors.affiliation: Italian Medicines Agency (AIFA), Rome, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Siviero
authors.affiliation: Independent Consultant in Reimbursement & Pharmacy, Zwolle, Netherlands.
authors.forename: Julius
authors.initials: J
authors.lastname: van Dam
authors.affiliation: Association Internationale de la Mutualité, Brussels, Belgium.
authors.forename: Jan
authors.initials: J
authors.lastname: Van Emelen
authors.affiliation: Alzheimer's Disease Research Centre, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Wimo
authors.affiliation: Alzheimer's Disease International (ADI), London, UK.
authors.forename: Marc
authors.initials: M
authors.lastname: Wortmann
authors.affiliation: Tapestry Networks (US Office), Waltham, MA, USA. Electronic address: lgoh@tapestrynetworks.com.
authors.forename: Lindee
authors.initials: L
authors.lastname: Goh
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis / Q000628:therapy; D001290:Attitude; D003695:Delivery of Health Care; D006801:Humans; D010348:Patient Care Team
keywords: Alzheimer's disease; Biomarker; Care standard; Clinical development; Collaboration; Diagnosis; Innovation; Multistakeholder; Payer; Reimbursement